These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28900813)

  • 1. Assessment of acute bowel function after radiotherapy for prostate cancer: Is it accurate enough?
    Bonet M; Cayetano L; Núñez M; Jovell-Fernández E; Aguilar A; Ribas Y
    Clin Transl Oncol; 2018 May; 20(5):576-583. PubMed ID: 28900813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scoring of treatment-related late effects in prostate cancer.
    Livsey JE; Routledge J; Burns M; Swindell R; Davidson SE; Cowan RA; Logue JP; Wylie JP
    Radiother Oncol; 2002 Nov; 65(2):109-21. PubMed ID: 12443807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study.
    Chopra S; Dora T; Chinnachamy AN; Thomas B; Kannan S; Engineer R; Mahantshetty U; Phurailatpam R; Paul SN; Shrivastava SK
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):630-5. PubMed ID: 24521678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pudendal nerve injury impairs anorectal function and health related quality of life measures ≥2 years after 3D conformal radiotherapy for prostate cancer.
    Yeoh EE; Botten R; Di Matteo A; Tippett M; Hutton J; Fraser R; Dinning PG; Wattchow D
    Acta Oncol; 2018 Apr; 57(4):456-464. PubMed ID: 29139310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
    Muanza TM; Albert PS; Smith S; Godette D; Crouse NS; Cooley-Zgela T; Sciuto L; Camphausen K; Coleman CN; Ménard C
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1316-21. PubMed ID: 16029787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
    Arcangeli S; Strigari L; Soete G; De Meerleer G; Gomellini S; Fonteyne V; Storme G; Arcangeli G
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):39-45. PubMed ID: 18538488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study.
    Pinkawa M; Holy R; Piroth MD; Fischedick K; Schaar S; Székely-Orbán D; Eble MJ
    Radiat Oncol; 2010 Apr; 5():27. PubMed ID: 20377874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer--predictive factors on irritative symptoms, incontinence and rectal bleeding.
    Pinkawa M; Piroth MD; Fischedick K; Nussen S; Klotz J; Holy R; Eble MJ
    Radiat Oncol; 2009 Sep; 4():36. PubMed ID: 19772568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of radiation-induced toxicity by in vitro radiosensitivity of lymphocytes in prostate cancer patients.
    Pinkawa M; Brzozowska K; Kriehuber R; Eble MJ; Schmitz S
    Future Oncol; 2016 Mar; 12(5):617-24. PubMed ID: 26806671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer.
    van der Laan HP; van den Bergh A; Schilstra C; Vlasman R; Meertens H; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1138-45. PubMed ID: 17931794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy.
    White EC; Murphy JD; Chang DT; Koong AC
    Am J Clin Oncol; 2015 Dec; 38(6):564-9. PubMed ID: 24401668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up.
    Lilleby W; Stensvold A; Dahl AA
    Acta Oncol; 2014 Oct; 53(10):1380-9. PubMed ID: 24844918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.
    Koper PC; Jansen P; van Putten W; van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC
    Radiother Oncol; 2004 Oct; 73(1):1-9. PubMed ID: 15465140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
    De Meerleer G; Vakaet L; Meersschout S; Villeirs G; Verbaeys A; Oosterlinck W; De Neve W
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):777-87. PubMed ID: 15465194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial.
    Rammant E; Ost P; Swimberghe M; Vanderstraeten B; Lumen N; Decaestecker K; Bultijnck R; De Meerleer G; Sarrazyn C; Colman R; Fonteyne V
    Strahlenther Onkol; 2019 May; 195(5):393-401. PubMed ID: 30406289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.
    Ghadjar P; Hayoz S; Bernhard J; Zwahlen DR; Hölscher T; Gut P; Guckenberger M; Hildebrandt G; Müller AC; Plasswilm L; Papachristofilou A; Stalder L; Biaggi-Rudolf C; Sumila M; Kranzbühler H; Najafi Y; Ost P; Azinwi NC; Reuter C; Bodis S; Kaouthar K; Wust P; Thalmann GN; Aebersold DM
    J Clin Oncol; 2015 Dec; 33(35):4158-66. PubMed ID: 26527774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.